Get the Stockscreener App
29.29
2.30%
-0.69
After Hours:
29.29
Enliven Therapeutics Inc stock is traded at $29.29, with a volume of 754.71K.
It is down -2.30% in the last 24 hours and up +8.52% over the past month.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
See More
Previous Close:
$29.98
Open:
$29.93
24h Volume:
754.71K
Relative Volume:
0.76
Market Cap:
$1.74B
Revenue:
-
Net Income/Loss:
$-97.21M
P/E Ratio:
-15.87
EPS:
-1.8459
Net Cash Flow:
$-71.82M
1W Performance:
-1.11%
1M Performance:
+8.52%
6M Performance:
+45.36%
1Y Performance:
+37.84%
1-Day Range:
$28.61
$30.20
1-Week Range:
$27.97
$30.63
52-Week Range:
$13.30
$30.63
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
29.29 | 1.78B | 0 | -97.21M | -71.82M | -1.8459 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Goldman | Buy |
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
View All
Enliven Therapeutics Inc Stock (ELVN) Latest News
Enliven Therapeutics (ELVN) Projected to Post Earnings on Thursday - Defense World
Enliven Therapeutics has cash runway into 2029 - BizWest
Enliven Therapeutics stock hits 52-week high at 30.29 USD - Investing.com
Enliven Therapeutics (NASDAQ:ELVN) Hits New 1-Year HighTime to Buy? - MarketBeat
ELVN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Enliven Therapeutics Q4 Loss Widens - marketscreener.com
Enliven Therapeutics (stock code: ELVN) recently released its financial report for the fourth quarter and full year of fiscal 2025, while also updating the market on the company's latest business developments. - Bitget
Enliven Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Enliven Therapeutics (NASDAQ: ELVN) advances ELVN-001 toward pivotal CML trial - Stock Titan
Enliven Therapeutics (NASDAQ: ELVN) touts ELVN-001 data and $462.6M cash runway - Stock Titan
Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - PR Newswire
ELVN: ELVN-001 shows strong efficacy in CML, with pivotal data and phase 3 launch expected in 2024 - TradingView
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update - ADVFN Ltd
ELVN SEC FilingsEnliven Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) Stock Rating Lowered by Wall Street Zen - MarketBeat
ELVN Should I Buy - Intellectia AI
Enliven Therapeutics, Inc. (ELVN) Stock Analysis: Exploring a 37.94% Upside Potential in Biotech - DirectorsTalk Interviews
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - PR Newswire
Insider Trends: Can Enliven Therapeutics Inc disrupt its industryJuly 2025 Recap & AI Powered Market Entry Strategies - baoquankhu1.vn
(ELVN) Risk Channels and Responsive Allocation - Stock Traders Daily
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Enliven Therapeutics, Inc. (ELVN) Stock Analysis: A Biotech Gem with 58% Upside and Strong Buy Ratings - DirectorsTalk Interviews
Enliven Therapeutics (NASDAQ:ELVN) Director Sells $32,201.40 in Stock - MarketBeat
Heyman, Enliven Therapeutics director, sells $32k in stock By Investing.com - Investing.com Canada
Plan-based 1,230-share sale by Enliven (ELVN) director disclosed - Stock Titan
Investment Report: Is SAIL forming a double bottomInsider Buying & Weekly Momentum Stock Picks - baoquankhu1.vn
Market Catalysts: Is Enliven Therapeutics Inc a speculative investment2025 Institutional Moves & Verified Entry Point Detection - baoquankhu1.vn
Gains Report: Is First Internet Bancorp showing insider buyingJuly 2025 Action & High Conviction Investment Ideas - baoquankhu1.vn
Enliven Therapeutics (NASDAQ: ELVN) seller files 75,000-share resale with Jefferies - Stock Titan
Stock Market Recap: How sensitive is Enliven Therapeutics Inc to inflationJuly 2025 Rallies & Safe Capital Investment Plans - baoquankhu1.vn
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Down 14.1% in January - MarketBeat
Can Enliven Therapeutics Inc disrupt its industryQuarterly Portfolio Summary & Breakout Confirmation Alerts - baoquankhu1.vn
Enliven Therapeutics (ELVN) CFO granted 150,000 options and 25,000 RSUs - Stock Titan
Will Enliven Therapeutics Inc. benefit from rising consumer demandJuly 2025 EndofMonth & Free Expert Verified Stock Movement Alerts - mfd.ru
What drives Enliven Therapeutics Inc.’s stock priceJuly 2025 Breakouts & Growth Focused Stock Reports - mfd.ru
Is Enliven Therapeutics Inc. stock attractive for income investorsProduct Launch & Daily Stock Trend Watchlist - mfd.ru
(ELVN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
History Review: Can Enliven Therapeutics Inc disrupt its industryWeekly Market Outlook & Smart Allocation Stock Tips - baoquankhu1.vn
Candriam S.C.A. Raises Stock Position in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Insider Sells $145,200.00 in Stock - MarketBeat
Lyssikatos, Enliven Therapeutics CSO, sells $145k in shares By Investing.com - Investing.com UK
Lyssikatos, Enliven Therapeutics CSO, sells $145k in shares - Investing.com
Aug Technicals: What drives Enliven Therapeutics Incs stock priceJuly 2025 Recap & Stepwise Trade Signal Implementation - baoquankhu1.vn
Bear Alert: Will AdvanSix Inc stock hit new highs in YEARQuarterly Earnings Summary & Safe Entry Trade Reports - baoquankhu1.vn
Enliven Therapeutics (NASDAQ:ELVN) Sets New 1-Year HighWhat's Next? - MarketBeat
Enliven Therapeutics, Inc. (ELVN): Investor Outlook with a 53.3% Potential Upside and Strong Buy Ratings - DirectorsTalk Interviews
Aug Highlights: How sensitive is Enliven Therapeutics Inc to inflation2025 Performance Recap & Breakout Confirmation Trade Signals - baoquankhu1.vn
Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k - AOL.com
Heron Therapeutics (NASDAQ:HRTX) & Enliven Therapeutics (NASDAQ:ELVN) Head to Head Contrast - Defense World
Update Report: Can Enliven Therapeutics Inc disrupt its industryPortfolio Gains Report & Fast Gaining Stock Reports - baoquankhu1.vn
Assessing Enliven Therapeutics (ELVN) Valuation After CSO Share Sale And Early Leukemia Trial Progress - Sahm
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Enliven Therapeutics Inc Stock (ELVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Collins Helen Louise | CHIEF MEDICAL OFFICER |
Feb 17 '26 |
Option Exercise |
2.48 |
45,000 |
111,600 |
70,000 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER |
Feb 17 '26 |
Sale |
26.17 |
45,000 |
1,177,862 |
25,000 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):